Skip to main content

Table 8 Multivariable logistic regression analysis of the relationship between treatment types received by the patient and major depressive disorder

From: The psychological impact of inflammatory bowel disease as regards anxiety and depression: a single-center study

 

Major depressive disorder

OR (CI 95%)

Test of significance

No (N = 46)

Yes (N = 59)

N (%)

N (%)

Value

p-value

Sig.

Oral mesalamine

No

14 (30.43%)

17 (28.81%)

1.08 (0.47–2.51)

X2 = 0.033

0.857C

NS

Yes

32 (69.57%)

42 (71.19%)

Topical mesalamine

No

44 (95.65%)

57 (96.61%)

0.77 (0.11–5.7)

 

1.00F

NS

Yes

2 (4.35%)

2 (3.39%)

Oral steroids

No

28 (60.87%)

41 (69.49%)

0.68 (0.3–1.54)

X2 = 0.853

0.356C

NS

Yes

18 (39.13%)

18 (30.51%)

Topical steroids

No

44 (95.65%)

59 (100%)

  

0.19F

NS

Yes

2 (4.35%)

0 (0%)

Azathioprine

No

16 (34.78%)

19 (32.2%)

1.12 (0.5–2.54)

X2 = 0.077

0.781C

NS

Yes

30 (65.22%)

40 (67.8%)

Biological therapy

No

37 (80.43%)

47 (79.66%)

1.05 (0.4–2.76)

X2 = 0.01

0.922C

NS

Yes

9 (19.57%)

12 (20.34%)

Type remicade 1–Humera 2

No

40 (86.96%)

51 (86.44%)

1.05 (0.34–3.26)

X2 = 0.006

0.939C

NS

Yes

6 (13.04%)

8 (13.56%)

Surgical intervention

No

43 (93.48%)

55 (93.22%)

1.04 (0.22–4.91)

 

1.00F

NS

Yes

3 (6.52%)

4 (6.78%)

Did you stop TTT?

No

40 (86.96%)

54 (91.53%)

0.62 (0.18–2.17)

 

0.529F

NS

Yes

6 (13.04%)

5 (8.47%)

  1. CChi-square test of significance (X2, chi-square test value). FMonte-Carlo Fisher’s exact test of significance